The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 4, 2012, Pages

  Kirsch, A H ^a   Riegelbauer, V ^a   Tagwerker, A ^b   Rudnicki, M ^b   Rosenkranz, A R ^a   Eller, K ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Glomerulonephritis; Mammalian target of rapamycin inhibition; Proteinuria; Rapamycin

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ALBUMINURIA; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; ENDOTHELIUM CELL; GENE EXPRESSION PROFILING; GLOMERULUS FILTRATION RATE; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LASER MICRODISSECTION; MACROPHAGE; MALE; MOUSE; NEPHRITIS; NEPHROTOXIC SERUM NEPHRITIS; NEPHROTOXICITY; NONHUMAN; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; TRANSCRIPTION INITIATION;

EID: 84865130666     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00180.2012     Document Type: Article

References (40)

1. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo M. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 177: 8338-8347, 2006.
2. Battaglia M, Stabilini A, Roncarolo M. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105: 4743-4748, 2005.
3. Bonegio RGB, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 16: 2063-2072, 2005.
4. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, Study Investigators ZEUS. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377: 837-847, 2011.
5. Daniel C, Renders L, Amann K, Schulze-Lohoff E, Hauser I, Hugo C. Mechanisms of Everolimus-Induced Glomerulosclerosis After Glomerular Injury in the Rat. Am J Transplant 5: 2849-2861, 2005.
6. Daniel C, Ziswiler R, Frey B, Pfister M, Marti HP. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Exp Nephrol 8: 52-62, 2000.
7. Duffield JS, Erwig LP, Wei X, Liew FY, Rees AJ, Savill JS. Activated macrophages direct apoptosis and suppress mitosis of mesangial cells. J Immunol 164: 2110-2119, 2000.
8. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF, ELITE-Symphony Study. PF, Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357: 2562-2575, 2007.
9. Eller K, Weber T, Pruenster M, Wolf AM, Mayer G, Rosenkranz AR, Rot A. CCR7 deficiency exacerbates injury in acute nephritis due to aberrant localization of regulatory T cells. J Am Soc Nephrol 21: 42-52, 2010.
10. Eremina V, Quaggin SE. The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 13: 9-15, 2004.
11. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber H, Kikkawa Y, Miner JH, Quaggin SE. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707-716, 2003.
12. Fujinaka H, Yamamoto T, Takeya M, Feng L, Kawasaki K, Yaoita E, Kondo D, Wilson CB, Uchiyama M, Kihara I. Suppression of antiglomerular basement membrane nephritis by administration of anti-monocyte chemoattractant protein-1 antibody in WKY rats. J Am Soc Nephrol 8: 1174-1178, 1997.
13. Gao W, Faia KL, Csizmadia V, Smiley ST, Soler D, King JA, Danoff TM, Hancock WW. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 72: 1199-1205, 2001.
14. Haidinger M, Poglitsch M, Geyeregger R, Kasturi S, Zeyda M, Zlabinger GJ, Pulendran B, Horl WH, Saemann MD, Weichhart T. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol 185: 3919-3931, 2010.
15. Hochegger K, Jansky GL, Soleiman A, Wolf AM, Tagwerker A, Seger C, Griesmacher A, Mayer G, Rosenkranz AR. Differential effects of rapamycin in anti-GBM glomerulonephritis. J Am Soc Nephrol 19: 1520-1529, 2008.
16. Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL, Eissa NT. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med 15: 267-276, 2009.
17. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model. II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12: 1448-1457, 2001.
18. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 12: 1434-1447, 2001.
19. Mack M, Cihak J, Simonis C, Luckow B, Proudfoot AE, Plachy J, Bruhl H, Frink M, Anders HJ, Vielhauer V, Pfirstinger J, Stangassinger M, Schlondorff D. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J Immunol 166: 4697-4704, 2001.
20. McIntosh LM, Barnes JL, Barnes VL, McDonald JR. Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol 155: 295-303, 2009.
21. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969, 2008.
22. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47: 1084-1093, 2006.
23. Ooi JD, Snelgrove SL, Engel DR, Hochheiser K, Ludwig-Portugall I, Nozaki Y, O'Sullivan KM, Hickey MJ, Holdsworth SR, Kurts C, Kitching AR. Endogenous foxp3(+) T-regulatory cells suppress antiglomerular basement membrane nephritis. Kidney Int 79: 977-986, 2011.
24. Panzer U, Schneider A, Wilken J, Thompson DA, Kent SB, Stahl RA. The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis. Kidney Int 56: 2107-2115, 1999.
25. Paust H, Ostmann A, Erhardt A, Turner J, Velden J, Mittrücker H, Sparwasser T, Panzer U, Tiegs G. Regulatory T cells control the Th1 immune response in murine crescentic glomerulonephritis. Kidney Int 80: 154-164, 2011.
26. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312: 724-729, 1984.
27. Rosenkranz AR, Mendrick DL, Cotran RS, Mayadas TN. P-selectin deficiency exacerbates experimental glomerulonephritis: a protective role for endothelial P-selectin in inflammation. J Clin Invest 103: 649-659, 1999.
28. Schena FP, Pascoe MD, Alberu J, Del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87: 233-242, 2009.
29. Schrijver G, Bogman MJ, Assmann KJ, de Waal RM, Robben HC, van Gasteren H, Koene RA. Anti-GBM nephritis in the mouse: role of granulocytes in the heterologous phase. Kidney Int 38: 86-95, 1990.
30. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, Shevach EM. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 184: 3433-3441, 2010.
31. Turner JE, Paust HJ, Steinmetz OM, Peters A, Meyer-Schwesinger C, Heymann F, Helmchen U, Fehr S, Horuk R, Wenzel U, Kurts C, Mittrucker HW, Stahl RA, Panzer U. CCR5 deficiency aggravates crescentic glomerulonephritis in mice. J Immunol 181: 6546-6556, 2008.
32. Urushihara M, Ohashi N, Miyata K, Satou R, Acres OW, Kobori H. Addition of angiotensin II type 1 receptor blocker to CCR2 antagonist markedly attenuates crescentic glomerulonephritis. Hypertension 57: 586-593, 2011.
33. Vierboom MP, Zavodny PJ, Chou CC, Tagat JR, Pugliese-Sivo C, Strizki J, Steensma RW, McCombie SW, Celebi-Paul L, Remarque E, Jonker M, Narula SK, Hart B. Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum 52: 627-636, 2005.
34. Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 84: 1492-1499, 2007.
35. Wang Y, Wang YP, Zheng G, Lee VWS, Ouyang L, Chang DHH, Mahajan D, Coombs J, Wang YM, Alexander SI, Harris DCH. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 72: 290-299, 2007.
36. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Hörl WH, Hengstschläger M, Müller M, Säemann MD. The TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory Response. Immunity 29: 565-577, 2008.
37. Wittmann S, Daniel C, Braun A, Vogelbacher R, Shimizu F, Kawachi H, Hugo C. The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat. Nephron Exp Nephrol 108: e45-e56, 2008.
38. Wolf D, Hochegger K, Wolf AM, Rumpold HF, Gastl G, Tilg H, Mayer G, Gunsilius E, Rosenkranz AR. CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol 16: 1360-1370, 2005.
39. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, Choe H, Sodroski J, Newman W, Koup RA, Mackay CR. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 185: 1681-1691, 1997.
40. Yi F, Dos Santos EA, Xia M, Chen Q, Li P, Li N. Podocyte injury and glomerulosclerosis in hyperhomocysteinemic rats. Am J Nephrol 27: 262-268, 2007.